Skip to main content
Article thumbnail
Location of Repository

High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases

By Velia D'Angelo, Stefania Crisci, Fiorina Casale, Raffaele Addeo, Maria Giuliano, Elvira Pota, Paola Finsinger, Alfonso Baldi, Roberto Rondelli, Alberto Abbruzzese, Michele Caraglia and Paolo Indolfi

Abstract

Studies on activated cell-signaling pathways responsible for neoplastic transformation are numerous in solid tumors and in adult leukemias. Despite of positive results in the evolution of pediatric hematopoietic neoplasias, there are some high-risk subtypes at worse prognosis. The aim of this study was to asses the expression and activation status of crucial proteins involved in cell-signaling pathways in order to identify molecular alterations responsible for the proliferation and/or escape from apoptosis of leukemic blasts. The quantitative and qualitative expression and activation of Erk-1, c-Jun, Caspase8, and Gadd45a was analyzed, by immunocytochemical (ICC) and western blotting methods, in bone marrow blasts of 72 patients affected by acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (ALL) and stage IV non-Hodgkin Lymphoma (NHL). We found an upregulation of Erk-1, Caspase8, c-Jun, and Gadd45a proteins with a constitutive activation in 95.8%, 91.7%, 86.2%, 83.4% of analyzed specimens, respectively. It is worth noting that all AML patients showed an upregulation of all proteins studied and the high expression of GADD45a was associated to the lowest DFS median (p = 0.04). On univariate analysis, only Erk-1 phosphorylation status was found to be correlated with a significantly shorter 5-years DFS in all disease subgroups (p = 0.033) and the lowest DFS median in ALL/NHL subgroup (p = 0.04). Moreover, the simultaneous activation of multiple kinases, as we found for c-Jun and Erk-1 (r = 0.26; p = 0.025), might synergistically enhance survival and proliferation potential of leukemic cells. These results demonstrate an involvement of these proteins in survival of blast cells and, consequently, on relapse percentages of the different subgroups of patients

Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2664791
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res
    2. (2000). An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia
    3. (2005). Apoptosis-based therapies for hematologic malignancies. Blood
    4. (2002). Association between avB6 integrin expression, elevated p42/44 MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
    5. (1999). Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.
    6. (2003). Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet Cytogenet
    7. (2001). Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent.
    8. (2002). Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res
    9. (2003). Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia.
    10. (2004). ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia
    11. (2007). ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood
    12. (1999). et al.: CR6: A third member
    13. (2006). Gadd45a and Gadd45b protect hematopoietic cells from UV-induced apoptosis via distinct signaling pathways, including p38 activation and JNK inhibition.
    14. (2004). Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther
    15. (2005). Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis. Oncogene
    16. (2005). Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res
    17. (2004). P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep
    18. (2005). Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL). Cancer Biol Ther
    19. (2006). Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood
    20. (1981). The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlation.
    21. (2001). Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.